chest CT (10/18) before and after treatment. In particular, we considered PFTs performed 6 months before RTX, at time 0, one year after the first RTX cycle, and at the end of follow-up (13.7±7.3 years). ILD extent score was assessed by the semi-quantitative method proposed by Goh et al (2008).¹

Results: Forced vital capacity (FVC%) significantly reduced during the year before RTX treatment [from 95.2±17.4 to 84.8±16.4; $p=0.0017$], as well as the diffusing capacity for carbon monoxide (DLCO%) [from 58.1±14.3 to 47.6±12.9; $p=0.0002$]. Conversely, FVC% and DLCO% stabilised one year after the first RTX cycle (80.8±23 and 47.8±15.7, respectively), and at the end of the follow-up (84.3±24.6 and 54.8±12.3, respectively; $p=0.0001$). In our cohort, only 7/10 patients had ILD detectable on CT before treatment. At the end of the follow-up we observed that ILD extended in 6/7 cases one patient remained stable, the three subjects without ILD did not developed pulmonary fibrosis.

Conclusions: According to PFTs results, our study showed that RTX could stabilise the progression of lung function tests in SSc patients. However, the semi-quantitative visual score identified radiological pulmonary worsening in many patient with stabilised PFTs. Therefore, the correlations between functional and radiological outcomes are so weak that many Authors suggested they should be considered together in SSc-ILD assessment.

REFERENCE:

- [1] Goh NSL, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. *Am J Respir Crit Care Med* 2008;177:1248–54.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6052

FRI0443 DIGITAL ARTERY VOLUME INDEX: THE FIRST OBJECTIVE, AUTOMATED, NON-INVASIVE IMAGING DIAGNOSTIC OF MACROVASCULAR INVOLVEMENT IN SSC

G. Lettieri¹, G. Abignano¹, G. Bagnato¹, S. Eng¹, J.P. Ridgeway¹, J.N. Kaftan², M. Hinton², O. Kubassova², M.H. Buch¹, P. Emery¹, P. O'Connor¹, F. Del Galdo¹.

¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; ²LAG, Image Analysis Group, London, UK

Background: Macrovascular involvement in Systemic Sclerosis (SSc) is caused by proliferation of vascular smooth muscle cells within the intima of arteries (neointimal proliferation). The resulting decrease in arterial volume is responsible for the severity of Raynaud's and for the onset of severe clinical manifestations such as Renal Crisis and Pulmonary Artery Hypertension.

Several RCTs have demonstrated the efficacy of Endothelin Receptor Antagonists (ERAs) in targeting neointimal proliferation, which makes them to date, the only disease modifying agent available in SSc. Nevertheless, the lack of validated early diagnostics means the intention to treat with ERAs remains limited to the diagnosis of end stage clinical manifestations of neointimal proliferation, such as presence of Digital Ulcer (DU) and PAH.

Objectives: Here we aimed to determine the proof of concept validity of automated Digital Artery Volume Index (DAVIX) measured by non-contrast Time of Flight (TOF) MRI as an objective diagnostic tool to be used as surrogate outcome measure of neointimal proliferation in SSc.

Methods: 10 Healthy Volunteers (HV) and 8 SSc patients were enrolled. Six patients underwent longitudinal assessments at least 12 months apart. MRI scans were performed on a 3T Magnetom Verio (Siemens) and consisted of a VIBE 3D T1 scan and a 2D TOF sequence of 8 min. DAVIX was calculated as the percentage of the ratio of digital artery and the respective finger volumes. The vessels and fingers were manually outlined by an expert radiologist and used as a 'gold standard' (DAVIX-1) and compared to a 2nd independent radiologist assessment (DAVIX-2). An automated segmentation algorithm was developed using threshold based segmentation and region growing (DAVIX-A) and validated against gold standard. Intraclass correlation coefficient (ICC) and absolute agreement were calculated to estimate reliability. Bland-Altman bias and 95% limits of agreement (LoA) were calculated as well.

Results: SSc patients and HV had comparable age (44±8 vs 45±8) and gender (F:M=5:2 vs 4:2). 4 fingers were affected by DUs at baseline and two fingers were affected by new DU at follow up. Mean(±SD) DAVIX in HV was 1.21 (±0.39) with no significant difference among individual fingers. Mean DAVIX in SSc patients was 0.37 (±0.18) and 0.32 (±0.39) at baseline and follow-up, respectively ($p<0.0001$ vs HV for both). The fingers with DU had an average DAVIX of 0.24 (±0.08) vs 0.40 (±0.18) of the fingers without DU ($p=0.02$). DAVIX changed over time in both directions. In the fingers affected by new DU, DAVIX dropped by 56% (0.161 vs 0.072) and 86% (1.149 vs 0.132), respectively. ICC among two independent readings was 0.90 (95% LoA -0.139, 0.118) with overall $r^2=0.74$ ($p<0.0001$). Automated segmentation showed superior correlation to gold standard with $r^2=0.80$ ($p<0.0001$).

Conclusions: This proof of concept study demonstrated validity and sensitivity to change of DAVIX for the automated volumetric assessment of digital arteries, which reflected clinical worsening in patients with new DU. Larger, longitudinal studies are planned to assess DAVIX' predictive value for the onset of DU and its potential use as early diagnostic of neointimal proliferation in SSc.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6616

FRI0444 PERIOSTIN IN SYSTEMIC SCLEROSIS: SERUM LEVELS AND SKIN EXPRESSION OF A NOVEL POSSIBLE BIOMARKER

G. De Luca¹, C. Campochiaro¹, S. Franchini¹, S. Burastero², S. Sartorelli¹, A. Giachi¹, G. Cavalli¹, C. Dogliani³, L. Dagna¹. ¹Unit of Rheumatology, Immunology, Allergy and Rare Diseases (UnIRAR); ²Cellular and molecular allergy; ³Unit of Pathology, San Raffaele Scientific Institute, Milan, Italy

Background: Periostin(PN), a matricellular protein, serves as a regulator of wound healing and fibrosis. PN^{-/-} mice develop lower degrees of fibrosis when exposed to bleomycin(BLM), suggesting a possible role in the pathogenesis of Systemic Sclerosis(SSc).¹ PN serum levels are increased in SSc and seem to be associated with skin disease severity.²

Objectives: To evaluate the role of serum PN as a biomarker of SSc severity, and to determine PN tissue expression in SSc patients.

Methods: PN serum levels were assessed by ELISA in 48 patients: 3 primary Raynaud's, 12 early SSc, 11 SSc without organ involvement, 22 SSc with organ involvement. All SSc patients met 2013 ACR/EULAR criteria. PN serum levels were evaluated in 28 sex-/age-matched healthy-controls(HCs). Data regarding disease subtypes and organ involvement were correlated. PN skin expression was determined by immunohistochemistry on paired involved and uninvolved skin biopsy samples in 10 patients(4 lcSSc and 6 dcSSc) in combination with a-SMA, CD68, CD3, CD4, CD8, CD163, CD20 and CD131.

Results: PN serum levels were higher in SSc patients compared to HCs(32.7 ±8.0 vs 27.7±7.3 ng/ml, $p<0.001$). Its levels were comparable among different groups. No differences in PN serum levels were detected when comparing disease subtypes, disease duration, presence and extent of organ involvement, autoantibodies profile and current or previous treatment. Higher PN levels were found in SSc patients with active pattern at nailfold videocapillaroscopy and a history of digital ulcers($p<0.02$). PN serum levels did not correlate with skin or lung disease extent. Skin samples from involved SSc skin showed high PN expression in the upper dermis and in the fibrotic area of the lower dermis(more evident in dcSSc), suggesting a role in skin fibrosis. In all SSc involved skin, PN was expressed in areas where ongoing fibroproliferation and macrophage/T lymphocytic infiltration occurred, indirectly suggesting a pathogenic role in inflammation driven-fibrosis. Interestingly, an identical PN immunohistochemical expression was evident in uninvolved dcSSc skin, but not in lcSSc skin.

Conclusions: In our cohort PN serum levels are elevated in SSc patients but they do not correlate with disease features. Its postulated role as a severity biomarker needs to be further elucidated. The different immunohistochemical expression of PN in uninvolved skin from dcSSc and lcSSc patients suggests a possible pathogenic role in the progressive inflammation-driven fibrosis that characterise diffuse cutaneous involvement.

REFERENCES:

- [1] Yang L, et al. Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma. *PLoSOne* 2012.
- [2] Yamaguchi Y, et al. Serum Periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. *Br J Dermatol* 2013.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5975

FRI0445 A RANDOMISED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF ORAL MYCOPHENOLATE MOFETIL WITH PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS RELATED EARLY INTERSTITIAL LUNG DISEASE

G. Naidu¹, S. Sharma¹, V. Dhir¹, S. Dhoria², A. Sinha³, A. Mb¹, S. Jain¹. ¹Internal Medicine; ²Pulmonary Medicine; ³Radiodiagnosis, PGIMER, Chandigarh, India

Background: Previous studies showed benefit of immunosuppressants in moderate to severe ILD in systemic sclerosis (SSc).^{1,2} Initiation of immunosuppression early in the course of SSc-ILD might help in halting disease process and improve long term morbidity and mortality.

Objectives: Aim of the study was to determine efficacy and safety of mycophenolate mofetil (MMF) in treating early and mild SSc-ILD (ILD on HRCT, FVC ≥70%

predicted). Primary outcome was to compare the change in FVC after 6 months of therapy with MMF or placebo. Secondary outcomes were change in SF-36v2, Mahler dyspnoea index (MDI) and adverse events profile of MMF and placebo.

Methods: This was a double-blind, randomised, placebo-controlled trial conducted at a tertiary care centre in north India. SSC-ILD patients with FVC $\geq 70\%$ and aged >18 years were randomised to receive either MMF (up to 2 g/day) or placebo for 6 months. FVC, DLCO, MRSS, SF36v2, MDI and 6 min walk distance (6MWD) were noted at baseline and 6 months. Outcome was categorised into improved/stabilised (any increase in FVC or fall in FVC $<10\%$ from baseline) and worsened (fall in FVC $\geq 10\%$ from baseline). Trial was approved by the institute ethics committee and was registered at ClinicalTrials.gov (NCT02896205).

Results: Forty-one subjects were included in the study (20 MMF and 21 placebo). Mean age was 40.3 ± 10.1 years and 95.1% were females. Median duration of illness was 5 years (IQR: 3–9). Mean baseline FVC was $81.71 \pm 9.35\%$, DLCO was $50.36 \pm 14.24\%$, MDI was 7.68 ± 2.72 , 6MWD was 423.61 ± 61.64 m, MRSS was 17.07 ± 8.36 . Fifteen subjects in MMF arm and 19 in placebo arm completed 6 months study duration. Mean change in FVC was $-1.79 \pm 7.32\%$ in MMF arm and $1.34 \pm 4.47\%$ in placebo arm. Mean absolute difference in FVC change from baseline to 6 months between the two arms was 3.13% (95% CI, -1.02 to 7.28 ; $p=0.131$). In mITT analysis, 15 subjects improved/stabilised and 5 subjects worsened in MMF arm compared to 19 and 2 subjects respectively in placebo arm. SF36v2 scores showed significant improvement in both the groups. No significant difference was noted between the two groups in mean change in focal score of MDI (3.33 vs 2.79; $p=0.638$), DLCO (2.46% vs 2.31%; $p=0.412$), 6MWD (2.8 m vs 12.11 m; $p=0.522$) and FVC among subjects with Scl-70 positivity (-2.19% vs 1.51% ; $p=0.184$). The MRSS decreased by a mean of 4.73 points in MMF arm compared to 1.53 points in placebo arm ($p=0.042$). MMF was well tolerated and rates of diarrhoea and infections were similar to that with placebo. Three subjects on MMF and 1 on placebo discontinued drugs.

Conclusions: In this small study, MMF for 6 months was not effective in stabilising the lung disease in early and mild SSC-ILD but was effective in controlling skin disease and was well tolerated.

REFERENCES:

- [1] Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med*. 2006;354:2655–66.
- [2] Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double blind, parallel group trial. *Lancet Respir Med*. 2016;4:708–19.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4673

FRI0446 INITIAL PREDICTORS FOR MORTALITY IN PATIENTS WITH CANCER-ASSOCIATED MYOSITIS: A MULTICENTER RETROSPECTIVE COHORT IN JAPAN

H. Kadota¹, T. Gono^{1,2}, Y. Yamaguchi³, E. Watanabe², Y. Okazaki¹, Y. Nakajima¹, S. Kobayashi¹, Y. Shirai¹, M. Takeno¹, C. Terai², M. Kuwana¹. ¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo; ²Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama; ³Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Background: Concomitant malignancy is one of the prognostic factors in patients with myositis,¹ but clinical parameters for mortality still remain unknown in patients with cancer-associated myositis (CAM).

Objectives: Initial predictors for mortality were examined using a multicenter cohort of CAM patients.

Methods: This retrospective study enrolled 67 consecutive patients diagnosed as having CAM in 3 referral hospitals between 1995 and 2017. Clinical data at diagnosis of myositis as well as treatment regimens and outcomes of myositis and malignancy were collected by review of medical charts. Myositis-specific autoantibodies (MSAs) were comprehensively detected using RNA immunoprecipitation (IP), enzyme-linked immunosorbent assay, and IP-immunoblotting. We initially conducted a univariate analysis to select variables that were different between survivors and dead cases. In multivariate analysis, the Cox proportional hazard model with backward selection method ($p > 0.20$) was employed to identify factors independently associated with mortality. Explanatory variables were chosen

based on the following three models. The Model 1 included age at diagnosis of myositis, gender and candidate variables ($p < 0.1$) selected by the univariate analysis. The Model 2 included age, gender, prognostic factors previously reported in myositis, such as dermatomyositis, dysphasia, interstitial lung disease (ILD), anti-ARS, and anti-MDA5, and malignancy type and staging, as explanatory variables. In the Model 3, age, gender, disease duration before diagnosis of myositis, period between diagnosis of myositis and tumour, myositis classification, MSAs, dysphasia, ILD, myositis disease activity after treatment, and malignancy type and staging were used as explanatory variables. Cumulative survivals calculated using the Kaplan-Meier method were compared between the patients with and without risk factors.

Results: The median age at diagnosis of myositis was 63 years, and 62% were female. MSAs were detected in 47 patients: anti-TIF1- γ in 27, anti-ARS in 6, anti-MDA5 in 5, anti-Mi-2 in 3, anti-NXP2 in 3, anti-SAE in 2, and anti-SRP in 1. During the median observation period of 2 years, 19 (28%) of 67 CAM patients were dead due to tumour in 16, ILD in 1, and an unknown cause in 2. The univariate analysis identified significant poor prognostic factors ($p < 0.1$) as follows: male ($p=0.04$), elder age at diagnosis of myositis ($p=0.08$), longer period between diagnosis of myositis and tumour ($p=0.07$), absence of breast cancer ($p=0.001$), malignancy stage III/IV ($p=0.006$). In multivariate analysis, male (HR 8.1, 95% CI 2.6–25.2; $p < 0.001$) and malignancy stage III/IV (HR 12.1, 95% CI 3.3–44.9; $p < 0.001$) were identified as independent risk factors for mortality in the Model 1, and identical variables were identified in the Models 2 and 3. Cumulative survival rates of patients with 0, 1, or 2 risk factors were 100%, 93%, and 69% at 1 year, and 100%, 82%, and 0% at 3 years, respectively. Cumulative survival rates were statistically different between the groups stratified by the number of risk factors (figure 1).

Abstract FRI0446 – Figure 1. Cumulative survival rates of patients with CAM with 0, 1, or 2 or risk factors.

Conclusions: Male and progression of malignancy at diagnosis of myositis were identified as predictors of survivals in CAM patients.

REFERENCE:

- [1] Callen JP. Dermatomyositis. *Lancet* 2000;355:53–7.

Disclosure of Interest: H. Kadota: None declared, T. Gono: None declared, Y. Yamaguchi: None declared, E. Watanabe: None declared, Y. Okazaki: None declared, Y. Nakajima: None declared, S. Kobayashi: None declared, Y. Shirai: None declared, M. Takeno: None declared, C. Terai: None declared, M. Kuwana: Grant/research support from: Astellas, Speakers bureau: Astellas and Japan Blood Products Organisation

DOI: 10.1136/annrheumdis-2018-eular.4042